Adagrasib [KRAZATI]

Abbreviation
MRTX849
Disease(s)
Non-Small Cell Lung Cancer (NSCLC)
Background
.pdf

Adagrasib is a small molecule anticancer medication used to treat non-small cell lung cancer. It is an inhibitor of G12C mutated KRAS GTPase a common mutation in some cancers.

This drug is missing the following documents, can you help us by contributing something?

Patent Information

Information of patent applications filed at local or international levels, that are contributed by the users of PODB as being relevant to this medicine

Please note that PODB does not provide and guarantee the comprehensive patent landscape in all countries.

*For more knowledge of patent search, please refer to the tutorial Step 2: Patent Search & Analysis
*For more information of the patent landscape on medicines, please also refer to WHO patent landscape reports, UNITAID patent landscape reports, Medicines Patent Pool Patent Status Database

Patent Applications

The table includes information of patent applications as filed in different countries, that are contributed by PODB users as being seen as relevant to this medicine.

CountryFiling datePriority dateApplicantNational numberInternational numberStatusPatent typeMore info
Europe (EPO)08-09-2022Mirati Therapeutics IncIN202417021715WO2023039020A1Under ExaminationProcessesView/Comment

Is something missing? Help us by contributing missing data: Contribute

↑ Back to Top